Trial reportBMC gastroenterology2022
Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study.
Trial report in BMC gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 3 syntheses or guidelines pooled it, 159 citations in OpenAlex.
- Prognostic value of the systemic immune-inflammation index in gastrointestinal cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Clinical utility of the pan-immune-inflammation value in breast cancer patients.Frontiers in oncology · 2023Pooled it
- Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors.Frontiers in immunology · 2023Pooled it
- Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial.Annals of surgical oncology · 2024Trial
- Trial
- Prognostic value of the nutritional risk index and prognostic nutritional index for immunotherapy outcomes in cervical Cancer.Gynecologic oncology reports · 2026Article
- Association Between Prognostic Nutritional Index and Clinical Outcomes After Percutaneous Coronary Intervention in Elderly Patients with Chronic Total Occlusion.Journal of cardiovascular development and disease · 2026Article
- Perioperative Risk Stratification in Surgically Treated Endometrial Cancer: The Impact of Nutritional Status and Comorbidity Burden on Morbidity and Survival.Annals of surgical oncology · 2026Article
- Association between prognostic nutritional index and clinical outcomes in patients with pyogenic liver abscess: a retrospective multicenter study.BMC infectious diseases · 2026Article
- A novel composite score based on NLR, PLR, and PNI for constructing a nomogram to predict overall survival in patients with gastric cancer.Discover oncology · 2026Article
- Dynamic machine learning model integrating resting energy expenditure for predicting postoperative complications after gastrectomy for gastric cancer.Journal of cancer research and clinical oncology · 2026Article
- Relationship Between Prognostic Nutritional Index and Stroke-Associated Pneumonia in Elderly Patients: A Two-Center Study of Spontaneous Intracerebral Hemorrhage.Food science & nutrition · 2026Article
- Integrating Blood-Based Immune-Inflammation Biomarkers into Artificial Intelligence-Driven Prognostic Models in Oncology.International journal of molecular sciences · 2026Review
- Inflammatory and Nutritional Indices as Prognostic Markers in Locally Advanced Gastric Cancer Treated with Neoadjuvant FLOT: A Retrospective Multicenter Study.Journal of clinical medicine · 2026Article
- Predictive role of systemic immune-inflammation index (SII) in tuberculosis infection morbidity and ICU tuberculosis patient mortality: an observational study.Journal of thoracic disease · 2026Article
- Prognostic Value of Baseline Systemic Immune-Inflammation Index in Advanced Intrahepatic Cholangiocarcinoma Treated with First-Line Gemcitabine-Cisplatin Plus PD-L1 Inhibitor: A Single-Center Retrospective Study.Current oncology (Toronto, Ont.) · 2026Article
- Prognostic Factors Impacting Surgical Resection Outcomes in Elderly Patients With Brain Metastasis.The Kaohsiung journal of medical sciences · 2026Article
- Construction and validation of a risk prediction model for perineural invasion in early gastric cancer based on multivariate analysis.BMC cancer · 2026Article
- Improving Prognostic Prediction in Head and Neck Cancer Through a Combined Systemic Immune-Inflammation Index and Prognostic Nutritional Index Score.Current oncology (Toronto, Ont.) · 2026Article
- Metabolic syndrome as an independent predictor of response and survival in locally advanced gastric cancer treated with neoadjuvant immunochemotherapy.Frontiers in oncology · 2026Article
71 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have confirmed that systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) can predict the prognosis and chemotherapy efficacy of various malignant tumors. However, to the best of our knowledge, no study investigated the SII combined with PNI score to predict the efficacy of anti-programmed death 1 (anti-PD-1) antibody sintilimab and XELOX regimen (capecitabine plus oxaliplatin) in the treatment of locally advanced gastric cancer. This study aims to evaluate the predictive value of pre-treatment SII-PNI score on the sensitivity of sintilimab immunotherapy combined with XELOX chemotherapy in patients with locally advanced gastric cancer.
methodsWe registered a prospective clinical study involving 30 locally advanced gastric cancer patients from March 2020 to July 2021. The pre-treatment SII and PNI were calculated from peripheral blood samples, and the cut-off value was calculated by receiver operating characteristic. The SII-PNI score ranged from 0 to 2 and were categorized into the following: score of 2, high SII (≥ 568.5) and low PNI (≤ 52.7); score of 1, either high SII or low PNI; score of 0, no high SII nor low PNI.
resultsAll patients were evaluated by RECIST1.1 criteria after four cycles of sintilimab immunotherapy combined with XELOX chemotherapy, including 5 patients with TRG 3 and 25 patients with non-TRG 3. The SII-PNI score of non-TRG 3 patients was significantly lower than that of TRG 3 patients (P = 0.017). The medial progression free survival of patients with low SII-PNI score was significantly better than that of patients with high SII-PNI score (P < 0.001). Multivariate analysis showed that SII-PNI score was an independent prognostic factor for predicting progression-free survival (P = 0.003).
conclusionThe pre-treatment SII-PNI score is a significant indicator for predicting chemosensitivity of locally advanced patients after sintilimab immunotherapy combined with XELOX chemotherapy, which can help to identify high-risk groups and predict prognosis.
trial registrationThe registered name of the trial is "Prospective clinical study of sintilimab combined with chemotherapy for neoadjuvant therapy in locally advanced gastric cancer". Its Current Controlled Trials number is ChiCTR2000030414. Its date of registration is 01/03/2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.